 | |
| Names | |
|---|---|
| IUPAC name 6-[2-Fluoro-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyridine-3-carboxamide | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| KEGG | |
| UNII | |
| |
| |
| Properties | |
| C20H24FN3O3 | |
| Molar mass | 373.428 g·mol−1 |
| Pharmacology | |
| N07BB06 (WHO) | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Ondelopran (LY-2196044) is an experimental drug being investigated for the treatment of alcoholism.[1]
Ondelopran appears to be anantagonist atopioid receptors,[2] which means it blocks the action of other opioids (including endogenous opioids like endorphins) by preventing them from binding to the receptor. It antagonizes the three primary opioid receptors with potency of 0.4 (mu), 0.6 (kappa), and 1.9 nM (delta).[3]
A study has shown that treatment with ondelopran reduces the amount of alcohol intake (significantly more than in the placebo group), which means it could be a good path for the treatment of alcoholism.[4] Another test also displays more results which go in the same conclusion.[3]
{{cite journal}}:Cite journal requires|journal= (help)